TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.

TRACON Pharmaceuticals Stock Performance

Shares of TRACON Pharmaceuticals stock opened at $0.07 on Friday. The firm has a fifty day moving average of $0.10 and a two-hundred day moving average of $0.96. The stock has a market capitalization of $233,244.00, a price-to-earnings ratio of 0.02 and a beta of 1.36. TRACON Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $14.75.

TRACON Pharmaceuticals (NASDAQ:TCON) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The business had revenue of $0.06 million during the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.